Aim: To characterize the longitudinal variability of estimated glomerular filtration rate (eGFR) in people with type 2 diabetes mellitus (T2DM), including variation between categories and individuals. Methods: People with T2DM and sufficient recorded serum creatinine measurements were identified from the Clinical Practice Research Datalink (T2DM diagnosis from 1 January 2009 to 1 January 2011 with 5 years follow-up); eGFR was calculated using the CKD-EPI equation.
| INTRODUCTION
Diabetes is a leading cause of chronic kidney disease (CKD) 1 and it is expected that between 40% and 50% of people with type 2 diabetes mellitus (T2DM) will be affected by CKD in their lifetimes. [2] [3] [4] However, only a small number of glucose-lowering therapies can be used safely in people with renal impairment without requiring a dose adjustment. 5 Therefore, renal function is an important factor to consider when prescribing glucose-lowering medications in people with T2DM.
Previous research has showed that renal function, as measured by estimated glomerular filtration rate (eGFR), can vary considerably, especially among people with diabetes. [6] [7] [8] [9] [10] [11] [12] [13] [14] These studies have also suggested that eGFR improvement among people with T2DM is possible, 11 leading to increased complexity when considering optimal treatment. Published studies have tended to investigate renal variation at the population or category level, with one such study reporting eGFR trends in the UK. 11 There are no recent studies reporting patient-level variation in renal function in a T2DM population.
Using primary care clinical records, this study aims to further characterize the longitudinal variability of eGFR in a cohort of people with T2DM with availability of consistent eGFR measurements over a period of 5 years to further explore eGFR trends and patterns over a longer period, including analysis at the individual patient level.
| MATERIALS AND METHODS

| Data source
Patient records were obtained from the UK Clinical Practice Research Datalink (CPRD), a primary care database that includes data from general practices throughout the UK. As of November 2018, the database contained anonymized data for approximately 10 million people, with over 1 in 10 practices in the UK contributing data. 15 CPRD data have been used in over 2000 peer-reviewed publications 15 , and have been found to be broadly representative of the UK population in terms of age, sex, ethnicity and body mass index (BMI). 16 Medical records are updated monthly from participating practices, including complete clinical information, pathology tests, anthropometric data, referral and prescription records. CPRD is linked to Hospital Episode Statistics (HES), a database containing details of all hospital admissions, accident and emergency attendances and outpatient appointments, to improve ethnicity recording for glomerular filtration rate (GFR) estimation. 17 
| Study population
Individuals were identified in CPRD based on their first diagnosis code of T2DM (codes are reported in the supporting information). Eligibility criteria included diagnosis of T2DM between 1 January 2009 and 1 January 2011; individuals also had to have a measure of serum creatinine after T2DM diagnosis (index measurement) and at least one measure of serum creatinine recorded in 5 yearly intervals post-first serum creatinine after diagnosis. In addition, the following inclusion criteria were applied: individuals must have at least 12 months' registration in practice prior to the index date; belong to an "up-to-standard" practice at the index date; have a record of ethnicity (identified through HES linkage, or CPRD if unavailable in HES). Individuals with a history of type 1 diabetes mellitus were excluded from the analysis.
| Renal function classification
Renal function was measured via eGFR using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. To estimate GFR, the CKD-EPI equation requires data for serum creatinine, age, sex and ethnicity (see equation in the supporting information). 18 The CKD-EPI equation was selected as it is the recommended formula by the National Institute for Heath and Care Excellence (NICE). 19 Individuals were grouped into GFR categories, as adopted by NICE guidelines, according to their eGFR at baseline and follow-up. 19 These are the same categories used by the Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group in their international guidelines for the management of CKD. 20 
| Data analysis
This was a retrospective, descriptive study. Individuals were grouped into the five clinical categories: G1 (>90 mL/min/1.73 m 2 ), G2 (60-89 mL/min/1.73 m 2 ), G3a (45-59 mL/min/1.73 m 2 ), G3b (30-44 mL/min/ 1.73 m 2 ) and G4 (15-29 mL/min/1.73 m 2 ) based on their renal function at baseline and according to each subsequent yearly measurement.
Category G5 (<15 mL/min/1.73 m 2 ) was also considered, but none of the study population had an eGFR that fitted within this group.
Baseline characteristics, including age at T2DM diagnosis, age at the index date, BMI, HbA1c, systolic blood pressure, diastolic blood pressure and eGFR, were compared among individuals included and excluded from the analysis using Student's t-test. Renal function was described for each yearly interval based on the last recorded value per year and compared with baseline using mean values, counts and percentages to identify the raw change in eGFR as well as individual category changes. The analysis was performed using Stata version 14.
| RESULTS
A total of 46 813 people with newly diagnosed T2DM were identified; of these, 7766 (16.6%) met the study inclusion criteria ( Figure S1 ). Most of the included population was white (91.7%), with South Asian, Black, Chinese and other ethnicities accounting for 4.8%, 1.7% and 1.4% of patients, respectively (Table S1 ). G2 was the most common GFR category, representing 50.2% (3900/7766) of the study population at the index date; 2550 (32.8%), 962 (12.4%), 307 (4.0%) and 47 (0.6%) were in categories G1, G3a, G3b and G4, respectively (Table S1 ). No patients were in category G5.
Of the 7766 patients included, only a small subset (1037) had a recorded albumin creatinine ratio (ACR). No patients had severely increased ACR (A3; >30 mg/mmol); approximately 24% (253/1037) had moderately increased ACR (A2; 3-30 mg/mmol) and 76% (784/1037) had normal ACR (A1; <3 mg/mmol).
On average, there were no relevant differences in the baseline characteristics of those included and excluded from the analysis in terms of age, BMI, HbA1c, systolic and diastolic blood pressure and eGFR (Table S1 ).
| Trend analysis
On average, the population's eGFR decreased by 0.44 mL/min/ 1.73 m 2 annually. However, an eGFR increase of 0.80 mL/min/ 1.73 m 2 was observed between the index measurement and year 1; this was followed by a steady eGFR decline ( Figure 1 ).
People in the G1 category at baseline presented with a steady eGFR decline of 1.28 mL/min/1.73 m 2 annually; those in categories G2, G3a and G3b presented with an eGFR increase between index and year 1, followed by a steady decline; and those in the G4 category showed an overall increase in eGFR of 1.85 mL/min/1.73 m 2 annually ( Figure 2 ).
| GFR category transition analysis
At year 5, 21.3% (1651/7766) of individuals had moved to a lower GFR category and 20% (1042/5216) had moved to a higher GFR category (Table 1) . Of the 1316 people in category G3a or below at baseline, 28.3% (373/1316) moved to G2 or above (eGFR ≥60 mL/min/1.73 m 2 ) at year 5.
During follow-up, patients changed GFR categories 1.5 times on average [standard deviation (SD) 1.6]. Those with reduced renal function below 60 mL/min/1.73 m 2 (G3 and higher categories) changed GFR categories more often compared with people with eGFR ≥60 mL/min/1.73 m 2 (G1 and G2) ( Table 2 ). In particular, people in categories G1 and G2 changed GFR categories 1.3 times on average (SD 1.6 and 1.5, respectively), and people in categories G3a, G3b and G4 changed GFR categories 2.6 (SD 1.7), 2.1 (SD 1.7) and 2.9 (SD 1.9) times, respectively. 
| Individual patient analysis
| Sensitivity analyses
An analysis of eGFR trends was performed based on the mean of all eGFR values per year, rather than the last recorded eGFR measurement. Overall, this analysis showed that the population's eGFR decreased by 0.45 mL/min/1.73 m 2 annually compared with 0.44 mL/min/1.73 m 2 in the main analysis. There was also an increase of 0.65 mL/min/1.73 m 2 in the first year, followed by a steady decline. Trends in the different GFR categories and at the individual patient level were very similar to those reported in the main analysis (Table S4 and Figure S3 , respectively). Table S4 ). Change in renal function in the GFR categories and at the individual patient level showed the same trends as reported in the main analysis (Table S4 and Figure S4 , respectively).
Finally, we also looked at eGFR trends according to ACR. The results in both categories (A1 and A2) followed a similar trend to that observed in the main analysis ( Figure S5 in the G2, G3a and G3b categories showed an increase at year 1 followed by decline; lastly, those in the G4 category showed an overall improvement over time. Individuals with an eGFR <60 mL/min/1.73 m 2 at baseline (G3a, G3b and G4) changed GFR categories more often than those in the higher categories. In addition, around 28% of people with eGFR <60 mL/min/1.73 m 2 at baseline had an increase in their eGFR to ≥60 mL/min/1.73 m 2 by year 5. While the change at the overall population level and in some GFR categories was small, there was a greater and more clinically relevant known. However, there are some limitations to this analysis. The study design may also have contributed to the increasing trend in eGFR for patients in the lower category (G4), because five serum creatinine measurements were required at yearly intervals following the index measurement. This criterion was needed to ensure that patients had enough data to allow sufficient follow-up, although it is possible that this could have led to the exclusion of individuals with low renal function who died over the study period thereby leaving a sample that overrepresented the G4 patients whose renal function increased over time. The majority of people were excluded because of a lack of serum creatinine measurements during the follow-up period (82.9%;
32 358 out of 39 047 excluded patients), although analysis showed that there were no relevant differences in the baseline characteristics between included versus excluded individuals.
The CKD-EPI equation was used in the main analysis as it is the method recommended by NICE for GFR estimation. 19 NICE recommend the CKD-EPI equation, as it is considered to be more accurate than the MDRD Study equation at the population level, less biased at a GFR of >60 mL/min/1.73 m 2 , and performs better in people aged 75 years and over. 19 However, it has been found to lack precision at the individual level. 22, 23 Therefore, we also performed a sensitivity 
